vTv Therapeutics Inc.
NASDAQ Capital MarketTotal Valuation
vTv Therapeutics Inc. carries a market capitalization of 108.61M, placing it among publicly traded companies globally. Its enterprise value stands at 61.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 108.61M |
| Enterprise Value | 61.65M |
Share Statistics
vTv Therapeutics Inc. currently has 3.94M shares outstanding.
| Shares Outstanding | 3.94M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
vTv Therapeutics Inc. trades at a trailing price-to-earnings ratio of 173.74. The price-to-sales ratio is 11.57, and the price-to-book ratio stands at 1.89.
| PE Ratio | 173.74 |
| PS Ratio | 11.57 |
| PB Ratio | 1.89 |
| P/TBV Ratio | 1.89 |
| P/FCF Ratio | -26.68 |
| P/OCF Ratio | -25.43 |
Enterprise Valuation
| EV / Sales | 1.67 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
vTv Therapeutics Inc. maintains a current ratio of 12.48, meaning it holds 12.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.48 |
| Quick Ratio | 12.35 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,540.83 |
Financial Efficiency
| Return on Equity (ROE) | -11.69 |
| Return on Assets (ROA) | -8.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 10.59 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
vTv Therapeutics Inc.'s stock has gained approximately 33.28481% over the past 52 weeks. The 50-day moving average sits at 31.32, while the 200-day moving average is 34.09.
| Beta (5Y) | N/A |
| 52-Week Price Change | 33.28481% |
| 50-Day Moving Average | 31.32 |
| 200-Day Moving Average | 34.09 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, vTv Therapeutics Inc. generated 36.84M in revenue and converted that into -4.76M in net income, yielding earnings per share of -0.54. EBITDA reached -9.24M, while operating income came in at -9.25M.
| Revenue | 36.84M |
| Gross Profit | N/A |
| Operating Income | -9.25M |
| Pretax Income | -6.40M |
| Net Income | -4.76M |
| EBITDA | -9.24M |
| EBIT | -9.25M |
| Earnings Per Share (EPS) | -0.54 |
Balance Sheet
Total book value stands at 78.63M, with working capital of 80.57M providing operational flexibility.
| Cash & Cash Equivalents | 86.64M |
| Total Debt | N/A |
| Net Debt | -86.64M |
| Equity (Book Value) | 78.63M |
| Book Value Per Share | 19.96 |
| Working Capital | 80.57M |
Cash Flow
vTv Therapeutics Inc. produced -16.76M in operating cash flow over the past twelve months.
| Operating Cash Flow | -16.76M |
| Capital Expenditures | N/A |
| Free Cash Flow | -16.76M |
| FCF Per Share | -1.48 |
Margins
vTv Therapeutics Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -25.11 and net profit margin of -12.91 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -25.11 |
| Pretax Margin | -17.38 |
| Profit Margin | -12.91 |
| EBITDA Margin | -25.10 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -52.25 |
| FCF Yield | -3.75 |
Stock Splits
vTv Therapeutics Inc.'s most recent stock split took place on November 21, 2023 with a 40:1 split ratio.
| Last Split Date | 11/21/2023 |
| Split Ratio | 40:1 |
Scores
vTv Therapeutics Inc. posts an Altman Z-Score of 6.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.06 |